{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.8","value":"8266"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"Part A Food effect: AUC0-t of DZD9008 under Fasted condition"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"67.5","value":"10050"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Part A Food effect: AUC0-t of DZD9008 under High-Fat Meal condition"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Area under the plasma concentration-time-curve from time zero the last quantifiable time point, calculated by the linear up/log down rule, in the fasted or fed state.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the Fasted or High-Fat Meal condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal or Fasted condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.","id":"OG000","title":"Part A Food Effect Cohort: Sunvozertinib 300 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants from the food effect cohort for whom a PK profile is available on at least one of the fed and fasted dosing days.","reportingStatus":"POSTED","timeFrame":"Day 1 and Day 9: 0 (predose) up to 168 hours.","title":"Part A Food Effect: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}